Shares of Gossamer Bio Inc (NASDAQ:GOSS) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $29.25.

Several analysts recently weighed in on GOSS shares. Svb Leerink started coverage on Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective for the company. Evercore ISI started coverage on Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective for the company. Barclays started coverage on Gossamer Bio in a report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price objective for the company. Zacks Investment Research downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Finally, Leerink Swann started coverage on Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating for the company.

Shares of GOSS traded up $1.20 during trading hours on Wednesday, reaching $20.49. 96,223 shares of the company traded hands, compared to its average volume of 284,955. The firm has a market capitalization of $1.35 billion and a P/E ratio of -0.91. Gossamer Bio has a 12-month low of $15.59 and a 12-month high of $25.06.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, May 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.27). As a group, equities analysts forecast that Gossamer Bio will post -3.37 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new stake in shares of Gossamer Bio in the first quarter valued at about $18,649,000. BlackRock Inc. bought a new stake in shares of Gossamer Bio in the first quarter valued at about $17,212,000. Federated Investors Inc. PA bought a new stake in shares of Gossamer Bio in the first quarter valued at about $15,992,000. Samsara BioCapital LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at about $11,548,000. Finally, Geode Capital Management LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at about $4,507,000. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: When is a capital gain realized?

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.